POLAR CAPITAL HEALTHCARE OPPORTUNITIES I GBP

Targets long term capital appreciation through investing in a global portfolio

  • 3916.00p Price (Inc)
  • - Price (Acc)
  • 0.00% 0.00%

    Initial charge
  • 1.00% Annual management charge
  • 1.15% Ongoing charges
  • 0.00% Yield

Fund data last updated 19 November 2019

The investment objective of the Fund is to preserve capital and achieve long term capital appreciation. The Fund will seek to achieve its investment objective by investing in a globally diversified portfolio of healthcare companies.

Fund summary

Sector Specialist
Structure OFFSHORE FUND
Launched April, 2009
Size £1,151m
Yield 0.00%
Charging basis
Dividends paid

Charges

Initial charge 0.00%
Initial charge via Bestinvest 0.00%
Additional bid/offer spread 0.00%
Annual management charge 1.00%
Ongoing charges figure 1.15%

Allocation

Proportion (%)

  • {{chartDataItem.text}}
    {{chartDataItem.value}}

Allocation

Proportion (%)

  • {{chartDataItem.text}}
    {{chartDataItem.value}}

Allocation

Proportion (%)

  • {{chartDataItem.text}}
    {{chartDataItem.value}}

Investment process

Manager research

Average monthly relative returns

Bestinvest MRI

14/15 15/16 16/17 17/18 18/19 3 years 5 years Career 3 years 5 years Career
0.00% 0.00% 0.00% -0.07% 0.35% 0.00% 0.00% -0.24% 0.00% 0.00% 38.20%

Performance figures are based on the average of monthly percentage returns relative to the benchmark index.

Gareth Powell / Daniel Mahony

Powell and Mahony are portfolio Manager’s and co-head’s of the Manager's Healthcare Business unit at Polar Capital LLP. Powell has over 10 years' investment experience in the healthcare sector, with over 8 years as a portfolio Manager. He joined Polar Capital in 2007 and is currently co-manager of the Polar Healthcare Opportunities Fund. Mahony has more than 11 years' investment experience in the healthcare sector, with over 2 years as a Portfolio Manager and 9 years as a sell-side analyst. Prior to joining Polar Capital, he was Head of the European Healthcare Research Team at Morgan Stanley, which covered the European Biotechnology, Medical.

Track record

Gareth Powell / Daniel Mahony has 2.7 years experience of managing mutual funds in this sector. Over this period the average monthly return relative to the benchmark index has been -0.24%. During the worst period of relative performance (from May 2009 - May 2011) there was a decline of 14% relative to the index. The worst absolute loss has been 16%.

Periods of worst performance

Absolute -16.00% (March 2010 - July 2010)
Relative -14.00% (May 2009 - May 2011)

About the MRI

Our unique indicator: the Bestinvest Manager Record Index (MRI) measures the likelihood that the fund manager is adding value through their decisions. It is based on their performance record over the course of their career, adjusted for the amount of risk taken. MRI is an important contributor to our fund rating system but it is also vital to take account of qualitative factors. It is also very important to select funds to form a cohesive portfolio with an appropriate overall risk level.

Allocation

Proportion (%)

  • {{chartDataItem.text}}
    {{chartDataItem.value}}

Allocation

Proportion (%)

  • {{chartDataItem.text}}
    {{chartDataItem.value}}

Allocation

Proportion (%)

  • {{chartDataItem.text}}
    {{chartDataItem.value}}

Top 10 holdings

Data accurate as at 31 October 2011

7.1% Johnson & Johnson
5.6% Roche Holding
5.5% Pfizer
5.4% Abbott Labs
4.1% Sanofi
3.1% Allergan
2.9% Celgene
2.6% Pharmasset
2.5% Amgen
2.5% Baxter International
Source: Polar Capital

Key Investor Documents

Download